top of page

Solomon. DELIVER Design Manuscript

Details of the DELIVER study design and statistical analysis

Solomon. DELIVER primary Manuscript

DELIVER primary results manuscript

Vaduganathan. SGLT2 Meta-analysis

Meta-analysis of DELIVER, EMPEROR-Preserved and other SGLT2 trials

Myhre. NT-proBNP in DELIVER

Influence of NT-proBNP on outcomes in DELIVER

Butt. Atrial fibrillation in DELIVER

Influence of atrial fibrillation on outcomes and effectiveness of dapagliflozin in DELIVER

Peikert. Age and Effectiveness and Safety of Dapagliflozin in DELIVER

Influence of Age on the safety and effectiveness of dapagliflozin in DELIVER

Desai. DELIVER DAPA-HF Cause of Death

Mode of death across the spectrum in ejection fraction in DAPA-HF and DELIVER

Lam. Solomon. On my mind...

Discussion of why the results of DELIVER suggest that SGLT2 inhibitors behave differently from other therapies in Heart Failure

McCausland. Renal Outcomes in DELIVER

Dapagliflozin and Kidney Outcomes in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fractio

Wang. Sex Differences in DAPA-HF and DELIVER

Effect of Dapagliflozin according to sex across the EF spectrum

Kosiborod. Effect of Dapagliflozin on Health Status and Quality of Life

Effect of Dapagliflozin on Health Status and Quality of Life in Mildly Reduced or Preserved Ejection Fraction

Talha. Population-Level Implications of Sodium-Glucose Cotransporter-2 Inhibitors for Heart Failure With Preserved Ejection Fraction in the US

Population-Level Implications of Sodium-Glucose Cotransporter-2 Inhibitors for Heart Failure With Preserved Ejection Fraction in the US

Butt. Dapagliflozin in Black and White Patients With Heart Failure Across the Ejection Fraction Spectrum

Dapagliflozin in Black and White Patients With Heart Failure Across the Ejection Fraction Spectrum

Vaduganathan. All-Cause Hospitalizations

Dapagliflozin and All-Cause Hospitalizations in Patients With Heart Failure With Preserved Ejection Fraction

Solomon. DELIVER Baseline Manuscript

Detailed baseline characteristics of DELIVE

Jhund. DAPA-HF DELIVER pooled

Prespecified pooled analysis of DELIVER and DAPA-HF

Cunningham. Dapagliflozin in hospitalized or recently hospitalized patients

Effect of dapagliflozin in hospitalized or recently hospitalized patients with mildly reduced or preserved ejection fraction

Adamson. BMI and Dapagliflozin in DELIVER

Influence of BMI on effectiveness of dapagliflozin in DELIVER

Butt. Frailty in DELIVER

Effect of frailty on effectiveness and safety of dapagliflozin in DELIVER

Ostrominski. NYHA in DELIVER

NYHA Class and effectiveness of Dapagliflozin and effect of dapagliflozin on NYHA class in DELIVER

Vaduganathan. Time to Clinical Benefit

Time to clinical benefit in DELIVER

Selvaraj. BP in DELIVER

Effect of blood pressure on efficacy of dapagliflozin and influence of dapagliflozin on blood pressure in DELIVER

Inzucchi. DELIVER Diabetes and Pre-Diabetes

Effect of Dapagliflozin on Patients with Diabetes or Pre-Diabetes and Heart Failure with Mildly Reduced or Preserved Ejection Fraction

Vardeny. Dapagliflozin in Heart Failure with Improved Ejection Fraction

Effect of Dapagliflozin in patients with heart failure with improved ejection fraction

Yang. Dapagliflozin in patients with heart failure with mildly reduced and preserved ejection fraction treated with a mineralocorticoid receptor antagonist or sacubitril/valsartan

Dapagliflozin in patients with heart failure with mildly reduced and preserved ejection fraction treated with a mineralocorticoid receptor antagonist or sacubitril/valsartan

Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials

Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials

Butt. Dapagliflozin and Gout

Association of Dapagliflozin Use With Clinical Outcomes and the Introduction of Uric Acid–Lowering Therapy and Colchicine in Patients With Heart Failure With and Without Gout
A Patient-Level Pooled Meta-analysis of DAPA-HF and DELIVER

bottom of page